Nutrition and disease progression pre–highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART?

Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART?

Several studies have investigated a variety of nutritional supplementation interventions in adults with HIV. In this narrative review, we summarize the evidence from 31 clinical trials that explore clinical benefits of macronutrient and micronutrient supplementation in this population while attempting to answer the question of whether good nutrition can delay the time to highly active antiretro...

Highly Active Antiretroviral Therapy (HAART) and Metabolic Complications

Effect of Highly Active Antiretroviral Therapy (HAART) on Human Immunodeficiency Virus Disease Pathogenesis and Progression

Human immunodeficiency virus (HIV), the causative agent of Acquired Immunodeficiency Syndrome (AIDS) was discovered way back in 1983. More than three decades since its discovery, HIV infection diagnosis, treatment and management has been a big challenge to the medical field. HIV infection is attributed to cause compromised T-cell and B-cell immunity, promote different malignancies and the infec...

Gynaecomastia associated with highly active antiretroviral therapy (HAART).

There is a global Acquired Immune Deficiency Syndrome (AIDS) epidemic. It is estimated that the total number of people living with Human Immune deficiency Virus (HIV) is 33.2 million in the year 2007. An estimated 2.1 million people died from AIDS in 2007. As highly active antiretroviral therapy (HAART) becomes more widely used, the side effects of this regime are becoming more evident in clini...

Starting highly active antiretroviral therapy: why, when and response to HAART.

Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of patients with HIV, although it remains unclear as to the best time to start treatment to reduce the risk of clinical progression. The initial virological response to HAART, by reducing viral load to below the limit of detection, is essential for reducing the risk of drug resistance, which in the longer term ...